Company intelligence / Profile preview

Stemregen

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Stemregen's products have been documented in internal studies to trigger the release of an average of 10 million additional stem cells from bone marrow per serving. The company claims this supports healthy aging and optimal health by enhancing the body's innate repair system. Their original formula has been rebranded as STEMREGEN® Release and expanded into new lines such as Sport, Mobilize, and Signal.

Therapeutic areas: OtherDermatology
Modalities: Plant-based supplementNutraceuticals
Industry: Food & Nutrition

Drug pipeline

4 assets

Release

Commercial

Indications: General wellness

3 more assets in the full pipeline.

Request access →

Partnerships

Being title sponsor at Dave Asprey's Biohacking Conference in Austin in 2025

Beyond the preview

Go deeper on Stemregen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stemregen.

Explore the full profile